Table 8 Relevant pharmacogenetics association studies that focused on serotonin receptor 2A (5HT2A)
From: Pharmacogenetics of antidepressant response: An update
Reference | Gene | Drug | Sample | Outcome measure | Results | p-value |
|---|---|---|---|---|---|---|
[50] | 5HT2A | Paroxetine | 166 unipolar depressed patients | HAMD | HTR2A C(1354)T polymorphism showed an association with remission and response | p = 0.002 p = 0.01 |
[90] | 5HT2A | Citalopram | 1953 depressed patients (STAR*D) | HAMD | Positive association with a marker in the 5HT2A gene | p range 1 × 10-6 to 3.7 × 10-5 |
[48] | 5HT2A | Fluoxetine | 96 subjects with unipolar major depression | HAMD | Positive association with three markers in the 5HT2A gene | p = 0.001-0.03 |
[91] | 5HT2A | Paroxetine, mirtazapine | 246 elderly patients with major depression | Discontinuation rates | The presence and the severity of paroxetine-induced side effects were strongly associated with the T(102)C C/C genotype | p = 0.001 |
[60] | 5HT2A | Fluvoxamine, paroxetine | 248 bipolar and 195 depressed patients | HAMD | Marginal association between with theT(102)C C allele and the antidepressant response | p = 0.001 |
[76] | 5HT2A | Various antidepressants | 173 patients with major depression and 121 healthy controls | HAMD | Association between T(102)C C allele and antidepressant response | p = 0.023 |
[66] | 5HT2A | Fluoxetine and paroxetine | 100 depressed patients | HAMD | HTR2A: -1438G/G associated with a good response and with nausea in paroxetine-treated patients | p = 0.010 p = 0.013 |